Clinical Trial

Machine Learning in Guiding rTMS Treatment for GWI-Related Headaches and Body Pain

Study acronym: SVM - GWI
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to create a machine learning algorithm to improve active repetitive transcranial magnetic stimulation (rTMS) treatments for veterans and/or active military personnel by alleviating Gulf War Illness related headaches and body pain (GWI-HAP). This study aims to develop and validate a Support Vector Machine (SVM) model that could replace the trial-and-error process by assessing functional connectivity provided by resting state functional magnetic resonance imaging (rs-fMRI) data to predict the most effective rTMS protocol for each person. All participants will be receiving active rTMS treatment. The main questions it intends to answer are: 1. Does the SVM model predict a more effective treatment response rate for predicted respondents undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) compared to predicted non-respondents? 2. Does the SVM model predict a more effective treatment response rate while undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) and left motor cortex (LMC) in predicted respondents compared to predicted non-respondents? Participants will undergo the following: 1. Receive a total of 13 active rTMS treatment sessions over 3-4 months. 2. Visit the clinic for a total of 15 visits for assessments, check ups, and treatments. 3. Keep a daily log of their headaches, muscle and joint pain throughout the study.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-04-14
notable Primary completion pushed: 2029-06 -> 2029-10 2026-04-14
minor Completion pushed: 2029-09 -> 2029-10 2026-04-14
Trial Details
NCT Number NCT07325513
Lead Sponsor Veterans Medical Research Foundation
Collaborators: San Diego Veterans Healthcare System, Congressionally Directed Medical Research Programs
Conditions Gulf War Illness, Headache, Muscle and Joint Pain
Enrollment 140 participants
Start Date 2026-03-25
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-13